Sanofi
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SNY research report →
Range $49 – $57
Price Chart
About the company
Sanofi is a global healthcare enterprise dedicated to the research, development, manufacturing, and commercialization of therapeutic solutions across the United States, Europe, and other international markets. Its business is structured into three primary divisions: Pharmaceuticals, Vaccines, and Consumer Healthcare. The Pharmaceuticals segment delivers specialized treatments, encompassing human monoclonal antibodies and therapies for a range of conditions such as multiple sclerosis, neurological disorders, various inflammatory and immunological diseases, rare disorders, oncology, and rare blood conditions.
- CEO
- Belén Garijo López
- IPO
- 2002
- Employees
- 76,493
- HQ
- Paris, IF, FR
AI snapshot
Six angles, distilled from the data.
The stock is in a constructive recovery regime, trading above both the 50-day and 200-day moving averages. It sits near the upper end of its 52-week range, which points to a multi-month uptrend rather than a broken chart, though it remains below the yearly high.
Street sentiment is mixed but leaning constructive: 12 Buy, 14 Hold, and 1 Sell, with a Hold consensus and a $53 median target versus a $48.37 close. The recent tone improved after Exane BNP Paribas upgraded the name to Outperform and lifted its target to $57.
Earnings momentum is solid, with 6 beats in the last 8 quarters and the most recent quarter topping estimates by 25.2%. Next-year EPS is modeled at 5.4255 versus 2.01 trailing, so shareholders should watch whether margin discipline and revenue growth keep supporting that step-up.
No notable insider activity in recent quarters. With no reported transactions, there is no clear discretionary buy or sell signal to read into.
Profitability is healthy, led by a 74.3% gross margin and a 22.28% operating margin, while revenue grew 15.7% year over year. Cash generation is strong at $14.12 billion of free cash flow, but net debt remains elevated at $11.86 billion.
Sanofi screens as a large-cap pharma name with a lower-beta, defensive profile and a valuation that still looks moderate at 10.54 times earnings. The setup favors investors who want cash flow and earnings stability rather than the fastest growth in the group.
Similar companies
Peers in the same neighborhood.
- Market Cap
- $111.70B
- P/E
- 24.05
- Fwd P/E
- 11.31
- PEG
- -0.45
- P/S
- 1.98
- P/B
- 1.38
- EV/EBITDA
- 7.76
- Div Yield
- 4.91%
- Gross Margin
- 73.44%
- Op Margin
- 21.55%
- Net Margin
- 8.19%
- ROE
- 5.84%
- ROIC
- 7.49%
Latest fiscal year · YoY change
- Revenue
- $46.72B+5.5%
- Gross Profit
- $33.67B+8.3%
- Op Income
- $9.60B
- Net Income
- $7.81B+40.5%
- EPS
- $3.20+45.8%
- OCF Growth
- +18.4%
- FCF Growth
- +22.5%
- 52W High
- $50.61
- 52W Low
- $39.07
- 50D MA
- $43.00
- 200D MA
- $44.36
- Beta
- 0.28
- RSI (14)
- 57
- Avg Volume
- 3.37M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Sanofi delivered strong Q3 growth and raised 2026 guidance, while also resetting its R&D and portfolio strategy to protect growth beyond Dupixent LOE.· October 30, 2026
- Q3 sales were EUR 14.4 billion, up 14.3%, with business EPS up 19.6% and gross margin up 2.1 points.
- Dupixent again led the quarter, with sales of EUR 5.7 billion and more than 1.5 million patients on treatment globally.
- New launches contributed approximately EUR 2.2 billion in Q3, up 19.2%, now about 15% of company sales.
- Sanofi discontinued amlitelimab and itepekimab and expanded its Regeneron alliance to add four next-generation immunology compounds.
- Full-year 2026 guidance was raised to low-teens sales growth and mid-teen business EPS growth, while vaccine sales are now expected to be down low-single digits for the year.
Q3 2026 net sales were EUR 14.4 billion, up 14.3% year over year. Gross margin improved by 2.1 percentage points, business operating income rose 19.7%, business operating margin expanded by 1.9 points, and business EPS increased 19.6%. Dupixent sales reached EUR 5.7 billion and rare disease sales were EUR 1.9 billion, up 12.6%; new launches were approximately EUR 2.2 billion, up 19.2%, and vaccines declined 7% versus last year. Management upgraded 2026 guidance to sales growth in the low-teens, which they said usually means 13%-15%, and business EPS growth in the mid-teens, usually 15%-17%. They also said vaccine sales for full-year 2026 are expected to decline by a low single-digit percentage.
Belén Garijo framed the quarter as evidence that Sanofi is executing well while reshaping the company for life after Dupixent LOE. She said the company is sticking to three focus areas—immunology, rare diseases, and vaccines—and is using pipeline pruning, simplification, business development, and M&A to strengthen long-term growth. Her tone was confident but disciplined, emphasizing accountability, cost discipline, and the need for external innovation alongside a stronger future R&D engine.
François Roger highlighted that Q3 growth was driven by demand, favorable gross-to-net effects, and product mix, with underlying group sales growth estimated at around 12% after excluding more one-off items. He said gross margin improved 2.1 points, OPEX was basically stable, BOI margin expanded 1.9 points, and business EPS rose 19.6%. He also flagged about EUR 500 million of BOI headwind in H2 2026 from the end of the Regeneron development reimbursement, said capital gains for 2026 are now expected to be around EUR 250 million, and reaffirmed strong cash flow, low leverage, dividend commitment, and capacity for disciplined BD and M&A.
Analysts focused heavily on Dupixent, 2027 pricing and growth, and how Sanofi plans to fund M&A and R&D while preserving balance sheet strength. Management said Dupixent demand remains strong, growth should moderate on a tougher base, and a normal U.S. Q1 gross-to-net seasonality step-down is likely in 2027, but they remained confident in reaching EUR 25 billion of Dupixent sales by 2030. On M&A, Belén and François stressed that deal-making will be disciplined and strategic, focused on later-stage and/or commercial assets, while Paolo explained that the frexalimab phase III trials were extended to collect sufficient events and strengthen statistical power.
The bull case from this call is that Sanofi is still showing strong underlying execution, with broad-based growth, margin expansion, and a raised 2026 outlook. Management is also actively reshaping the pipeline and external innovation strategy, including the expanded Regeneron alliance, to reduce reliance on Dupixent over time and preserve earnings and cash flow.
The main risks are Dupixent dependence, eventual loss of exclusivity, and the need to replenish the pipeline after discontinuing amlitelimab and itepekimab. Management also acknowledged that pricing should normalize in 2027, vaccines are expected to be down low-single digits in 2026, and some of the recent gross-to-net and operational benefits may not recur. R&D remains in reset mode, with Paolo noting Sanofi still lags peers in pipeline size and that more work is needed to improve productivity and success rates.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 90.0%
- Shares Outstanding
- 2.40B
- Float Shares
- 2.16B
of shares held by institutions
747 13F filers
Congressional trading
Senate and House stock disclosures for SNY, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Alan ArmstrongSenate | Buy | Mar 30, 26 | Filing → |
| Lisa C. McClainHouse · MI09 | Sell | Sep 11, 25 | Filing → |
| Lisa C. McClainHouse · MI09 | Buy | Aug 4, 25 | Filing → |
| Lisa C. McClainHouse · MI09 | Buy | Jun 17, 25 | Filing → |
| Lisa C. McClainHouse · MI09 | Sell | Jul 22, 25 | Filing → |
| John JamesHouse · MI10 | Sell | Sep 4, 24 | Filing → |
| John JamesHouse · MI10 | Buy | Nov 10, 23 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Oct 13, 23 | Filing → |
| Ro KhannaHouse · CA17 | Sell | Sep 8, 23 | Filing → |
| Ro KhannaHouse · CA17 | Sell | Aug 11, 23 | Filing → |
| Daniel GoldmanHouse · NY10 | Sell | Jul 10, 23 | Filing → |
| Ro KhannaHouse · CA17 | Buy | May 12, 23 | Filing → |
| Daniel GoldmanHouse · NY10 | Sell | Feb 27, 23 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Feb 10, 23 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Dodge & Cox | 15.67M | ▼ 12.42M |
| Morgan Stanley | 14.90M | ▲ 4.20M |
| Fisher Asset Management, LLC | 9.60M | ▼ 1.03M |
| Bank Of America Corp | 7.84M | ▼ 168.36K |
| Jpmorgan Chase & Co | 7.33M | ▲ 757.05K |
| Invesco Ltd. | 6.27M | ▼ 527.01K |
| Mondrian Investment Partners Ltd | 5.65M | ▲ 129.57K |
| Millennium Management LLC | 5.60M | ▲ 1.87M |
| Federated Hermes, Inc. | 5.46M | ▲ 1.61M |
| Brandes Investment Partners, LP | 4.31M | ▲ 169.86K |
| Boston Partners | 4.00M | ▲ 154.97K |
| Fmr LLC | 3.97M | ▲ 288.73K |
Held by 75 ETFs
Biggest fund positions in SNY by dollar value.
Our SNY coverage
Recent articles, reports, and earnings notes.

Sanofi (SNY): Dupixent Growth Supports a Hold
Sanofi combines strong Dupixent momentum, improving margins, and solid cash generation with a more leveraged balance sheet and a valuation that looks fair rather than cheap. The result is a patient Hold case for medium-term investors.

Windward Bio Group AG IPO: The Bull and Bear Case
Windward Bio Group AG (NASDAQ: WWB) is expected to list on November 13, 2026, on the Nasdaq exchange, with the price range not disclosed. The setup is straightforward: a clinical-stage biotech with a differentiated dosing story, but no revenue and heavy trial risk.

What to Watch as Bambusa Therapeutics Prices Its Nasdaq IPO
Bambusa Therapeutics Inc. (Nasdaq: BBTX) is expected to list on 2026-10-30, with pricing already set for the NASDAQ. The company has not disclosed a price range, but it sold 10,555,555 shares at $16.00 each for $168.9 million in gross proceeds. Bulls will focus on its long-acting bispecific pipeline in immunology and inflammation; bears will focus on clinical risk and a cash runway that the company says is not enough to fund 12 months of operations.
Want a deeper read on SNY?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Potential Sanofi-Insmed Deal: Analysts Split on Financial Strain Versus Pipeline Gains
benzinga.com · Nov 20
Sanofi Maps Vaccine Pipeline With Flu-COVID and Pneumococcal Trial Results Ahead
marketbeat.com · Nov 20
Insmed shares jump 18% as Sanofi weighs potential takeover
proactiveinvestors.com · Nov 19
As Sanofi's Pompe drug shortage drags on, some patients struggle to access treatments
cnbc.com · Nov 19
Sanofi Reportedly Gears Up For The Biggest Biotech Deal In Years
investors.com · Nov 19
3 Big Pharma Dividend Stocks Built for Retirement Income
247wallst.com · Nov 19
2 Growth Stocks to Buy in November Without Any Hesitation
fool.com · Nov 19
Sanofi's Next-Generation Rabies Vaccine Secures Approval in EU
zacks.com · Nov 19
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
AI analysis · Last refreshed November 14, 2026 · Live quote · Not investment advice